IPSEY Stock - Ipsen S.A.
Unlock GoAI Insights for IPSEY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $3.57B | $3.31B | $3.16B | $2.75B | $2.69B |
| Gross Profit | $2.96B | $2.74B | $2.63B | $2.31B | $2.20B |
| Gross Margin | 82.7% | 82.7% | 83.3% | 84.0% | 81.7% |
| Operating Income | $496.70M | $816.00M | $729.90M | $824.70M | $524.80M |
| Net Income | $345.90M | $644.40M | $648.60M | $646.60M | $548.00M |
| Net Margin | 9.7% | 19.5% | 20.5% | 23.5% | 20.4% |
| EPS | $1.05 | $1.87 | $1.80 | $1.91 | $1.65 |
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 12th 2023 | UBS | Upgrade | Buy | - |
| February 16th 2023 | Morgan Stanley | Upgrade | Equal Weight | - |
| December 6th 2022 | Barclays | Resumed | Equal Weight | - |
| September 28th 2022 | RBC Capital Mkts | Initiation | Sector Perform | - |
Earnings History & Surprises
IPSEYEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 11, 2026 | — | — | — | — |
Q2 2025 | Jun 30, 2025 | $1.63 | $1.18 | -27.6% | ✗ MISS |
Q4 2024 | Dec 31, 2024 | — | $0.35 | — | — |
Q2 2024 | Jun 29, 2024 | $1.26 | $0.75 | -40.7% | ✗ MISS |
Q4 2023 | Dec 31, 2023 | $1.42 | $1.48 | +4.2% | ✓ BEAT |
Q2 2023 | Jun 30, 2023 | $1.37 | $0.64 | -53.2% | ✗ MISS |
Q4 2022 | Dec 31, 2022 | $1.34 | $0.82 | -38.4% | ✗ MISS |
Q2 2022 | Jun 30, 2022 | $1.11 | $1.24 | +11.7% | ✓ BEAT |
Q4 2021 | Dec 31, 2021 | $1.19 | $1.17 | -1.7% | ✗ MISS |
Q2 2021 | Jun 30, 2021 | $1.16 | $1.08 | -6.9% | ✗ MISS |
Q4 2020 | Dec 31, 2020 | $1.06 | $1.20 | +13.2% | ✓ BEAT |
Q2 2020 | Jun 30, 2020 | $1.03 | $0.75 | -27.4% | ✗ MISS |
Q4 2019 | Dec 31, 2019 | $0.95 | $-0.92 | -196.5% | ✗ MISS |
Q2 2019 | Jun 30, 2019 | — | $0.75 | — | — |
Q4 2018 | Dec 31, 2018 | — | $0.68 | — | — |
Q2 2018 | Jun 30, 2018 | — | $0.69 | — | — |
Q4 2017 | Dec 31, 2017 | — | $0.51 | — | — |
Q2 2017 | Jun 30, 2017 | — | $0.43 | — | — |
Q4 2016 | Dec 31, 2016 | — | $0.29 | — | — |
Q2 2016 | Jun 30, 2016 | — | $0.45 | — | — |
Latest News
Frequently Asked Questions about IPSEY
What is IPSEY's current stock price?
What is the analyst price target for IPSEY?
What sector is Ipsen S.A. in?
What is IPSEY's market cap?
Does IPSEY pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to IPSEY for comparison